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Abstract
Background: p53AIP1 is a potential mediator of apoptosis depending on p53, which is mutated in
many kinds of carcinoma. High survivin expression in non-small cell lung cancer is related with poor
prognosis. To investigate the role of these genes in non-small cell lung cancer, we compared the
relationship between p53AIP1 or survivin gene expression and the clinicopathological status of lung
cancer.
Materials and methods: Forty-seven samples from non-small cell lung cancer patients were
obtained between 1997 and 2003. For quantitative evaluation of RNA expression by PCR, we used
Taqman PCR methods.
Results:  Although no correlation between p53AIP1 or survivin gene expression and
clinicopathological factors was found, the relationship between survivin gene expression and nodal
status was significant (p = 0.03). Overall survival in the p53AIP1-negative group was significantly
worse than in the positive group (p = 0.04); however, although survivin expression was not a
prognostic factor, the combination of p53AIP1 and survivin was a significant prognostic predictor
(p = 0.04). In the multivariate cox proportional hazard model, the combination was an independent
predictor of overall survival (p53AIP1 (+) survivin (+), HR 0.21, 95%CI = [0.01–1.66]; p53AIP1 (+)
survivin (-), HR 0.01, 95%CI = [0.002–0.28]; p53AIP1 (-) survivin (-), HR 0.01, 95%CI = [0.002–3.1],
against p53AIP1 (-) survivin (+), p = 0.03).
Conclusion: These data suggest that the combination of p53AIP1 and survivin gene expression
may be a powerful tool to stratify subgroups with better or worse prognosis from the variable non-
small cell lung cancer population.
Introduction
A number of genes for apoptosis play an important role in
tumorigenesis [1]. Several gene abnormalities were
reported as prognostic markers of non-small cell lung can-
cer, such as p53 [2]; however, these processes are complex
and remain unclear.
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The abnormal expression of p53 is frequently reported in
a variety of cancers [3]. p53 mutations are generally more
common in smokers than in nonsmokers and an excess of
G to T transversions of p53 has been described as a molec-
ular signature of tobacco smoke mutagens in smoking-
associated lung cancers. There are also mutational
hotspots (codons 157, 158, 245, 248, and 273) in the p53
gene in lung cancer [4]. Several reports have shown that
p53 expression is a prognostic marker in non-small cell
lung cancer [2]. p53 protein is a tumor suppressor gene
and mediates cell cycle arrest or programmed cell death
[5,6]. These p53-mediated events were triggered through
the transactivation of specific genes, including p21,
GADD45, cyclin G1, Bax, and fas [7,8].
Recently, we reported that p53AIP1, which is a new poten-
tial mediator of p53-dependent apoptosis, is associated
with prognosis in non-small cell lung cancer [9]. p53AIP1
is not normally expressed in any tissues except the thy-
mus, but is induced when Ser-46 of p53 was phosphor-
ylated after severe DNA damage [10,11]. Only a few
papers have reported p53AIP1 function in cancer biology
and it has not been well investigated [9,12].
On the other hand, survivin is a member of the IAP gene
family, which has been implicated in both the inhibition
of apoptosis and mitosis regulation [13]. Survivin up-reg-
ulates genes in tumor tissues [14]. High survivin expres-
sion in the primary tumor is related to poor prognosis in
many cancer types [15-20]. As p53 leads to the repression
of survivin expression [21], p53 AIP1 might act inversely
against survivin in the same manner as p53. It is interest-
ing to evaluate both the expression of the p53AIP1 gene
and survivin in primary non-small cell lung cancer.
In this study, we demonstrated the expression of these
genes in non-small cell lung cancer and normal lung tis-
sue, and the combination of p53AIP1 with survivin may
be a prognostic marker.
Methods
Patients and Samples
This study was approved by the Institutional Review
Board of the National Hospital Organization Kumamoto
Medical Center (Kumamoto, Japan) and all patients com-
pleted informed consent forms. Forty-seven operative
samples from non-small cell lung cancer (NSCLC)
patients were obtained at the National Hospital Organiza-
tion Kumamoto Medical Center (Kumamoto, Japan)
between May 1997 and September 2003. The samples
were histologically diagnosed as primary non-small cell
lung cancer according to the WHO classification. None of
the cases had received radiation therapy or chemotherapy
before surgery. Adjacent normal lung tissue was also taken
from all cases. Tissue specimens were frozen immediately
with RNA later™(QIAGEN) and stored at -80°C until RNA
extraction. RNA from tissue samples was prepared using
TRIzol reagents (Invitrogen). To evaluate cigarette con-
sumption, a smoking index (SI) was used: cigarette con-
sumption per day multiplied by smoking years. Referring
to this index, smokers were divided into 2 groups, heavy
smokers with indices ≥ 400, and light smokers < 400.
Quantitative PCR analysis
For quantitative evaluation of the RNA expression by PCR,
we used Taqman PCR methods (TaqMan® Gene Expres-
sion Assays; Applied Biosystems, Tokyo, Japan) as previ-
ously reported [22]. The p53AIP1 gene was amplified by
the following primer set as follows, reverse: ggggacttctcag-
gtcgtgt, forward: tggacttcttcatgccccga.
The p53AIP1 gene internal probe was ttgcggtgcgagtcgt-
ggaagtaa. Survivin was amplified by the following primer
set: reverse: ggggacttctcaggtcgtgt, forward: tggacttctt cat-
gccccga. The survivin internal probe was ttgcggt-
gcgagtcgtgg aagtaa.
PCR amplification condition were one cycle of 50°C, 2
min, and 95°C, 10 min followed by 50 cycles of 95°C, 15
sec and 60°C, 1 min. The measured value was calculated
by comparative Ct methods [22] and GAPDH gene ampli-
fication was used as a control. All reactions were dupli-
cated. The amounts of p53AIP1 and survivin mRNA were
expressed as n-fold GAPDH mRNA and the levels were
compared relative to adjacent normal lung tissues. A
tumor/normal ratio of p53AIP1 and survivin mRNA
expression greater than 1 was identified as a positive
expression, and the others as negative.
Statistical analysis
All statistical analysis was performed using Stat View J5.0
(SAS Institute Inc.). Different variables of tumors and nor-
mal tissues were analyzed with the chi-square test or
Fisher's exact test. Overall survival was analyzed using the
Kaplan-Meier method and evaluated by the log-rank test.
Significant differences were considered at p < 0.05. The
cutoff point was also p < 0.05 for univariate and multivar-
iate Cox proportional hazard model analysis.
Results
p53AIP1 and survivin expression in primary non-small
cell lung cancer (NSCLC) was evaluated by real-time RT-
PCR. All 47 samples were studied with paired histopatho-
logically normal lung tissues which were far from the
tumor margin. Table 1 shows a correlation between the
clinicopathological status and p53AIP1 and survivin gene
expressions. Although no relationship between the
p53AIP1 gene expression and variables (age, sex, smoking
index (SI), tumor size, nodal status, histological type) was
not found, the survivin gene expression-positive rates inJournal of Experimental & Clinical Cancer Research 2009, 28:22 http://www.jeccr.com/content/28/1/22
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the node metastasis-positive group were significantly
higher than in the negative group (p = 0.03).
Figure 1 shows the overall survival curves by Kaplan-Meier
analysis for patients with non-small cell lung cancer clas-
sified according to p53AIP1 expression (positive, tumor/
normal ratio 1; negative, <1). Patients in the positive
p53AIP1 expression group have a better prognosis than
the negative expression group (p = 0.04). The median fol-
low-up period was 5.4 years (1.2 to 8.4 years); however,
the superiority of the survivin expression negative group
to the positive group for overall survival was not signifi-
cant (Figure 2). When we compared the prognosis accord-
ing to the variable combination between p53AIP1 and
survivin, the p53AIP (+) survivin (-) group had the best
prognosis (Figure 3). In contrast, the p53AIP (-) survivin
(+) group showed the worst prognosis and the other two
Table 1: Correlation between p53AIP1 or survivin expression and clinicopathological characteristics
Characteristics All patients p53AIP1 positive p Survivin positive p
Age <70 19 11 14
≥70 28 14 0.23 14 0.45
Sex male 14 6 11
female 33 19 0.36 17 0.08
Smoking <400 19 10 13
index ≥400 28 15 0.95 15 0.31
Tumor T1 27 16 18
T2 16 9 8
T3 4 0 0.08 2 0.52
Nodal status N0 33 12 10
N1 14 5 0.17 9 0.03*
Histologic type Ad 27 12 19
Sq 16 10 7
others 4 3 0.34 2 0.22
Ad, adenocarcinoma; Sq, squarmous cell carcinoma
* statistically significant
Overall survival curves according to p53AIP1 gene expres- sion Figure 1
Overall survival curves according to p53AIP1 gene 
expression. Differences are significant (p = 0.04). Number 
of patients in each group, positive, 22; negative, 25.
Overall survival curves according to survivin gene expression Figure 2
Overall survival curves according to survivin gene 
expression. Differences are not significant (p = 0.36. 
Number of patients in each group, positive, 28; negative, 19.Journal of Experimental & Clinical Cancer Research 2009, 28:22 http://www.jeccr.com/content/28/1/22
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groups were intermediate. In univariate analysis using
age, tumor size, lymph node metastasis, histological type,
survivin expression, p53AIP1 expression, and the combi-
nation of p53AIP1 and survivin, p53AIP1 and the combi-
nation were statistically significant (Table 2).
In multivariate Cox proportional hazard model analysis,
the combination (p = 0.03) was an independent predictor
of overall survival (Table 2).
Discussion
The molecular mechanism of tumor progression and
apoptosis is still unclear. Several predictors, such as nodal
involvement, tumor stage, and survivin and p53 have
been reported; however, the relationship between p53 or
survivin and the prognosis of lung cancer patients is still
controversial [2,23]. As we recently reported, p53AIP1 in
primary non-small cell lung caner has a potential role as a
prognostic factor [9]. Additionally, the other report
showed that truncating variants of P53AIP1 were associ-
ated with prostate cancer [12]. A recent report showed that
p53AIP1 was directly regulated by not only p53 but p73
[24]. This might be supported by the result which did not
show a correlation between p53 mutation and p53AIP1
expression [9], and it may be interesting to investigate the
p73 expression with p53AIP1. The present study showed
that p53AIP1 is not related to any clinicopathological fac-
tors, which is different from the report that p53AIP1 is
closely related to nodal status in our previous study [9].
This might be due to different analysis methods, the fre-
quency or quantification of expression levels. Although
univariate analysis showed that p53AIP1, a proapoptotic
gene, is a good predictor of overall survival despite no cor-
relation with several factors, multivariate analysis did not
show this because of the limited sample size.
On the other hand, as previously reported, survivin-posi-
tive expression correlated with more aggressive behavior
and poorer prognosis [13]. Meta-analysis of the role of
survivin showed that positive survivin might be a prog-
nostic factor [23]. In our study, survivin is significantly
related to the nodal status, which may suggest that sur-
vivin plays the key role in lymph node metastasis, as in the
previous report [25]; however, survivin was not a signifi-
cant prognostic factor in the present study. It is difficult to
estimate the prognostic value of survivin because the
power of this study was low due to the limited sample
size; therefore, we considered the combination of biomar-
kers to be more powerful to show the prognostic value of
survivin and p53 AIP1.
The rationale was as follows, since p53 leads to the repres-
sion of survivin expression, and apoptotic cells induced
by p53 caused resistance to apoptosis when survivin was
overexpressed [21], p53 AIP1 might have an inverse effect
against survivin in the same manner as p53. Furthermore,
as the relationship between survivin and p53AIP1 has not
been investigated, we hypothesized that the combination
analysis of survivin with p53AIP1 can be a powerful tool
for risk stratification. The combination of negative
p53AIP1 and positive survivin showed the worst progno-
sis, leading to the speculation that these two genes act in
an opposite manner and are critical for tumor progres-
sion. Multivariate analysis showed that the combination
of these genes was an independent predictor of survival.
Furthermore, p53AIP1 and survivin expressions in non-
small cell lung cancer cells before chemotherapy may con-
tribute as independent predictors of the effect of chemo-
therapy, such as DNA-damaging agents.
In conclusion, although the sample size was small, our
study demonstrated that the combination of survivin with
p53AIP1 gene expression in non-small cell lung cancer is
a possible independent prognostic factor. Further investi-
gation of these combinations might show the prognostic
significance of these genes in non-small cell lung cancer.
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